Peptidomimetic competitive inhibitors of protein tyrosine phosphatases

Current Pharmaceutical Design

Volumn 16, Issue 28, 2010, Pages 3101-3117

  Shen, Kui ^a   Qi, Lixin ^a   Stiff, Lynn ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Activity based probe; Peptidomimetic competitive inhibitor; Phosphopeptide substrate; Phosphotyrosine analog; Protein tyrosine phosphatase inhibitor; Substrate trapping mutant

Indexed keywords

AMINO ACID; ASPARTYLALANYLASPARTYLGLUTAMYL PHOSPHOTYROSINAMIDE; BENZOIN; CELL PENETRATING PEPTIDE; DEXOYBENZOIN; HEPTAPEPTIDE; INSULIN RECEPTOR; MALONIC ACID; PEPTIDE DERIVATIVE; PEPTIDOMIMETIC AGENT; PHOSPHOAMINO ACID; PHOSPHOPEPTIDE; PHOSPHORUS; PHOSPHOTYROSINE; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; SULFUR; TRIPEPTIDE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; CARBON NUCLEAR MAGNETIC RESONANCE; CARBOXY TERMINAL SEQUENCE; COMBINATORIAL CHEMISTRY; COMBINATORIAL LIBRARY; COMPETITIVE INHIBITION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HUMAN; MOLECULAR INTERACTION; MOLECULAR SIZE; NITROGEN NUCLEAR MAGNETIC RESONANCE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY; YERSINIA;

ANIMALS; BINDING, COMPETITIVE; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PEPTIDES; PEPTIDOMIMETICS; PHOSPHOTYROSINE; PROTEIN TYROSINE PHOSPHATASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78649840566     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210793292537     Document Type: Review

References (136)

1. Hunter T. Signaling - 2000 and beyond. Cell 2000; 100: 113-27.
2. Zhang ZY. Chemical and mechanistic approaches to the study of protein tyrosine phosphatases. Acc Chem Res 2003; 36: 385-92.
3. Alonso A, Sasin J, Bottini N, et al. Protein tyrosine phosphatases in the human genome. Cell 2004, 117: 699-711.
4. Burke TR Jr, Zhang ZY. Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery. Biopolymers 1998; 47: 225-41.
5. Johnson TO, Ermolieff J, Jirousek MR. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Disc 2002; 1: 696-709.
6. Taylor SD. Inhibitors of protein tyrosine phosphatase 1B (PTP1B). Curr Top Med Chem 2003; 3: 759-82.
7. Liu G. Protein tyrosine phosphatase 1B inhibition: opportunities and challenges. Curr Med Chem 2003; 10: 1407-21.
8. van Huijsduijnen RH, Sauer WHB, Bombrun A, Swinnen D. Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs. J Med Chem 2004; 47: 4142-6.
9. Dewang PM, Hsu NM, Peng SZ, Li WR. Protein tyrosine phosphatases and their inhibitors. Curr Med Chem 2005; 12: 1-22.
10. Bialy L, Waldmann H. Inhibitors of protein tyrosine phosphatases: next-generation drugs? Angew Chem Int Ed 2005; 44: 3814-39.
11. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 2006; 7: 833-46.
12. Blaskovich MA. Drug discovery and protein tyrosine phosphatases. Curr Med Chem 2009; 16: 2095-176.
13. Combs AP. Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer. J Med Chem 2010; 53: 2333-2344.
14. Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999; 283: 1544-8.
15. Klaman LD, Boss O, Peroni OD, et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 2000; 20: 5479-89.
16. Cho H, Krishnaraj R, Itoh M, et al. Substrate specificities of catalytic fragments of protein tyrosine phosphatases (HPTP??, LAR, and CD45) toward phosphotyrosylpeptide substrates and thiophosphotyrosylated peptides as inhibitors. Protein Sci 1993; 2: 977-84.
17. Hiriyanna KT, Baedke D, Baek KH, Forney BA, Kordiyak G, Ingebritsen TS. Thiophosphorylated substrate analogs are potent active site-directed inhibitors of protein-tyrosine phosphatases. Anal Biochem 1994; 223: 51-8.
18. Hiriyanna KT, Buck WR, Shen SS, Ingebritsen TS. Thiophosphorylated RCM-lysozyme, an active site-directed protein tyrosine phosphatase inhibitor, inhibits G2/M transition during mitotic cell cycle and uncouples MPF activation from G2/M transition. Exp Cell Res 1995; 216: 21-9.
19. Jenkins KE, Higson AP, Seeberger PH, Caruthers MH. Solid-phase synthesis and biochemical studies of O-boranophosphopeptides and O-dithiophosphopeptides. J Am Chem Soc 2002; 124: 6584-93.
20. Zhang ZY, Maclean D, McNamara DJ, Sawyer TK, Dixon JE. Protein tyrosine phosphatase substrate specificity: size and phosphotyrosine positioning requirements in peptide substrates. Biochemistry 1994; 33: 2285-90.
21. Marseigne I, Roques BP. Synthesis of new amino acids mimicking sulfated and phosphorylated tyrosine residues. J Org Chem 1988; 53: 3621-4.
22. Burke TR Jr, Russ P, Lim B. Preparation of 4-[bis(tert-butyl)- phosphonomethyl]-N-Fmoc-D,L-phenylalanine; a hydrolytically stable analogue of O-phosphotyrosine potentially suitable for peptide synthesis. Synthesis 1991; 11: 1019-20.
23. Chatterjee S, Goldstein BJ, Csermely P, Shoelson SE. Phosphopeptide substrates and phosphonopeptide inhibitors of protein-tyrosine phosphatases. Peptides: chemistry and biology. In: Rivier JE, Smith JA, Eds. Leiden, Netherland: Escom Science 1992; pp. 553-5.
24. Burke TR Jr, Lee K. Phosphotyrosyl mimetics in the development of signal transduction inhibitors. Acc Chem Res 2003; 36: 426-33.
25. Yao ZJ, Lee K, Burke TR Jr. Incorporation of phosphotyrosyl mimetic 4-(phosphonodifluoromethyl)phenylalanine (F2Pmp) into signal transduction-directed peptides. Methods Mol Biol 2005; 298: 91-103.
26. Burke TR Jr. Design and synthesis of phosphonodifluoromethyl phenylalanine (F2Pmp): a useful phosphotyrosyl mimetic. Curr Top Med Chem 2006; 6: 1465-71.
27. Burke TR Jr, Kole HK, Roller PP. Potent inhibition of insulin receptor dephosphorylation by a hexamer peptide containing the phosphotyrosyl mimetic F2Pmp. Biochem Biophys Res Commun 1994; 204: 129-34.
28. Hussain M, Ahmed V, Hill B, Ahmed Z, Taylor SD. A reexamination of the difluoromethylenesulfonic acid group as a phosphotyrosine mimic for PTP1B inhibition. Bioorg Med Chem 2008; 16: 6764-77.
29. Chen L, Wu L, Otaka A, et al. Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases? Biochem Biophys Res Commun 1995; 216: 976-84.
30. Kotoris CC, Wen W, Lough A, Taylor SD. Preparation of chiral - monofluoroalkylphosphonic acids and their evaluation as inhibitors of protein tyrosine phosphatase 1B. J Chem Soc Perkin Trans 1 2000; 1271-81.
31. Montalibet J, Skorey K, McKay D, Scapin G, Asante-Appiah E, Kennedy BP. Residues distant from the active site influence protein-tyrosine phosphatase 1B inhibitor binding. J Biol Chem 2006; 281: 5258-66.
32. Boresch S, Leitgeb M, Beselman A, MacKerell AD Jr. Unexpected relative aqueous solubilities of a phosphotyrosine analogue and two phosphonate derivatives. J Am Chem Soc 2005; 127: 4640-8.
33. Gao Y, Wu L, Luo JH, Guo R, Yang D, Zhang ZY, Burke TR Jr. Examination of novel non-phosphorus-containing phosphotyrosyl mimetics against protein-tyrosine phosphatase-1B and demonstration of differential affinities toward Grb2 SH2 domains. Bioorg Med Chem Lett 2000; 10: 923-7.
34. Beaulieu PL, Cameron DR, Ferland JM, et al. Ligands for the tyrosine kinase p56lck SH2 domain: discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements. J Med Chem 1999; 42: 1757-66.
35. Liotta AS, Kole HK, Fales HM, Roth J, Bernier M. A synthetic trissulfotyrosyl dodecapeptide analogue of the insulin receptor 1146- kinase domain inhibits tyrosine dephosphorylation of the insulin receptor in situ. J Biol Chem 1994; 269: 22996-3001.
36. Desmarais S, Jia Z, Ramachandran C. Inhibition of protein tyrosine phosphatases PTP1B and CD45 by sulfotyrosyl peptides. Arch Biochem Biophys 1998; 354: 22--31.
37. Liu S, Dockendorff C, Taylor SD. Synthesis of protected L-4- [sulfono(difluoromethyl)]phenylalanine and its incorporation into a peptide. Org Lett 2001; 3: 1571-74.
38. Leung C, Grzyb J, Lee J, et al. The difluoromethylenesulfonic acid group as a monoanionic phosphate surrogate for obtaining PTP1B inhibitors. Bioorg Med Chem 2002; 10: 2309-23.
39. Chen YT, Xie J, Seto CT. Peptidic alpha-ketocarboxylic acids and sulfonamides as inhibitors of protein tyrosine phosphatases. J Org Chem 2003; 68: 4123-5.
40. Hill B, Ahmed V, Bates D, Taylor SD. Enantioselective synthesis of protected L-4-[sulfonamido(difluoromethyl)] phenylalanine and L-4-[sulfonamido(methyl)]phenylalanine and an examination of Hexa- and tripeptide platforms for evaluating pTyr mimics for PTP1B inhibition. J Org Chem 2006; 71: 8190-7.
41. Burke TR Jr, Yao ZJ, Zhao H, et al. Enantioselective synthesis of nonphosphorus-containing phosphotyrosyl mimetics and their use in the preparation of tyrosine phosphatase inhibitory peptides. Tetrahedron 1998; 54: 9981-94.
42. Fretz H. O-(carboxydifluoromethyl)-L-tyrosine: design and synthesis of a novel non phosphorous-containing phosphotyrosine isostere. Tetrahedron 1998; 54: 4849-58.
43. Kole HK, Akamatsu M, Ye B, et al. Protein-tyrosine phosphatase inhibition by a peptide containing the phosphotyrosyl mimetic, LO- malonyltyrosine. Biochem Biophys Res Commun 1995; 209: 817-22.
44. Burke TR Jr, Ye B, Akamatsu M, et al. 4'-O-[2-(2-fluoromalonyl)]- L-tyrosine: a phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides. J Med Chem 1996; 39: 1021-7.
45. Lee K, Gao Y, Yao ZJ, et al. Tripeptide inhibitors of Yersinia protein-tyrosine phosphatase. Bioorg Med Chem Lett 2003; 13: 2577-81.
46. Kang SU, Gao Y, Wu L, Zhang ZY, Burke TR Jr. Enantioselective synthesis of (S)-3-carboxy-4-((carboxy)difluoromethyl)phenylalanine in protected form and its incorporation into a PTP-1Bdirected tripeptide. Chem Biodivers 2004; 1: 626-33.
47. Lee K, Boovanahalli SK, Nam KY, et al. Synthesis of tripeptides as potent Yersinia protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett 2005; 15: 4037-42.
48. Akamatsu M, Roller PP, Chen L, Zhang ZY, Ye B, Burke TR Jr. Potent inhibition of protein-tyrosine phosphatase by phosphotyrosine-mimic containing cyclic peptides. Bioorg Med Chem 1997; 5: 157-63.
49. Roller PP, Wu L, Zhang ZY, Burke TR Jr. Potent inhibition of protein-tyrosine phosphatase-1B using the phosphotyrosyl mimetic fluoro-O-malonyl tyrosine (FOMT). Bioorg Med Chem Lett 1998; 8: 2149-50.
50. Hooft van Huijsduijnen R, Wälchli S, Ibberson M, Harrenga A. Protein tyrosine phosphatases as drug targets: PTP1B and beyond. Expert Opin Ther Targets 2002; 6: 637-47.
51. Vetter SW, Keng YF, Lawrence DS, Zhang ZY. Assessment of protein-tyrosine phosphatase 1B substrate specificity using inverse alanine scanning. J Biol Chem 2000; 275: 2265-8.
52. Garaud M, Pei D. Substrate profiling of protein tyrosine phosphatase PTP1B by screening a combinatorial peptide library. J Am Chem Soc 2007; 129: 5366-7.
53. Thakkar A, Wavreille AS, Pei D. Traceless capping agent for peptide sequencing by partial edman degradation and mass spectrometry. Anal Chem 2006; 78: 5935-9.
54. Köhn M, Gutierrez-Rodriguez M, Jonkheijm P, et al. A microarray strategy for mapping the substrate specificity of protein tyrosine phosphatase. Angew Chem Int Ed Engl 2007; 46: 7700-3.
55. Wang P, Fu H, Snavley DF, Freitas MA, Pei D. Screening combinatorial libraries by mass spectrometry. 2. Identification of optimal substrates of protein tyrosine phosphatase SHP-1. Biochemistry 2002; 41: 6202-10.
56. Sahoo H, Hennig A, Florea M, Roth D, Enderle T, Nau WM. Single-label kinase and phosphatase assays for tyrosine phosphorylation using nanosecond time-resolved fluorescence detection. J Am Chem Soc 2007; 129: 15927-34.
57. Wakata A, Cahill SM, Blumenstein M, et al. A mechanistic design principle for protein tyrosine kinase sensors: application to a validated cancer target. Org Lett 2008; 10: 301-4.
58. Tremblay MS, Lee M, Sames D. A luminescent sensor for tyrosine phosphorylation. Org Lett 2008; 10: 5-8.
59. Mitra S, Barrios AM. Highly sensitive peptide-based probes for protein tyrosine phosphatase activity utilizing a fluorogenic mimic of phosphotyrosine. Bioorg Med Chem Lett 2005; 15: 5142-5.
60. Mitra S, Barrios AM. A series of peptide-based, fluorogenic probes for protein tyrosine phosphatase activity. Anal Biochem 2007; 370: 249-51.
61. Mitra S, Barrios AM. Identifying selective protein tyrosine phosphatase substrates and inhibitors from a fluorogenic, combinatorial peptide library. Chembiochem 2008; 9: 1216-9.
62. Shah A. How to choose an in vitro kinase assay. Drug Disc Develop 2004; 7: 59-64.
63. Rininsland F, Xia W, Wittenburg S, et al. Metal ion-mediated polymer superquenching for highly sensitive detection of kinase and phosphatase activities. Proc Natl Acad Sci USA 2004; 101: 15295-300.
64. Ojida A, Mito-oka Y, Sada K, Hamachi I. Molecular recognition and fluorescence sensing of monophosphorylated peptides in aqueous solution by bis(zinc(II)-dipicolylamine)-based artificial receptors. J Am Chem Soc 2004; 126: 2454-63.
65. Sakamoto T, Ojida A, Hamachi I. Molecular recognition, fluorescence sensing, and biological assay of phosphate anion derivatives using artificial Zn(II)-Dpa complexes. Chem Commun 2009; 141-52.
66. Myers JK, Widlanski TS. Mechanism-based inactivation of prostatic acid phosphatase. Science 1993; 262: 1451-3.
67. Born TL, Myers JK, Widlanski TS, Rusnak F. 4-(Fluoromethyl) phenyl phosphate acts as a mechanism-based inhibitor of calcineurin. J Biol Chem 1995; 270: 25651-5.
68. Shen K, Qi L, Ravula M. Facile incorporation of a phosphatase activity-dependent quinone methide generating motif into phosphotyrosine. Synthesis 2009; 3765-8.
69. Shen K, Qi L, Ravula M, Klimaszewski K. Synthesis and peptide incorporation of an unnatural amino acid containing activity-based probe for protein tyrosine phosphatases. Bioorg Med Chem Lett 2009; 19: 3264-7.
70. Kalesh KA, Tan LP, Lu K, Gao L, Wang J, Yao SQ. Peptide-based activity-based probes (ABPs) for target-specific profiling of protein tyrosine phosphatases (PTPs). Chem Commun 2010; 46: 589-91.
71. Betley JR, Cesaro-Tadic S, Mekhalfia A, et al. Direct screening for phosphatase activity by turnover-based capture of protein catalysts. Angew Chem Int Ed Engl 2002; 41: 775-7.
72. Wälchli S, Espanel X, Harrenga A, Rossi M, Cesareni G, Hooft van Huijsduijnen R. Probing protein-tyrosine phosphatase substrate specificity using a phosphotyrosine-containing phage library. J Biol Chem 2004; 279: 311-8.
73. Sun H, Tan LP, Gao L, Yao SQ. High-throughput screening of catalytically inactive mutants of protein tyrosine phosphatases (PTPs) in a phosphopeptide microarray. Chem Commun 2009; 677-9.
74. Skorey KI, Kennedy BP, Friesen RW, Ramachandran C. Development of a robust scintillation proximity assay for protein tyrosine phosphatase 1B using the catalytically inactive (C215S) mutant. Anal Biochem 2001; 291: 269-78.
75. Shen K, Keng YF, Wu L, Guo XL, Lawrence DS, Zhang ZY. Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure. J Biol Chem 2001; 276: 47311-9.
76. Zhang S, Chen L, Kumar S, Wu L, Lawrence DS, Zhang ZY. An affinity-based fluorescence polarization assay for protein tyrosine phosphatases. Methods 2007; 42: 261-7.
77. Espanela X, van Huijsduijnenb RH. Applying the SPOT peptide synthesis procedure to the study of protein tyrosine phosphatase substrate specificity: probing for the heavenly match in vitro. Methods 2005; 35: 64-72.
78. Espanel X, Huguenin-Reggiani M, van Huijsduijnen RH. The SPOT technique as a tool for studying protein tyrosine phosphatase substrate specificities. Protein Sci 2002; 11: 2326-34.
79. Thingholm TE, Jensen ON. Enrichment and characterization of phosphopeptides by immobilized metal affinity chromatography (IMAC) and mass spectrometry. Methods Mol Biol 2009; 527: 47-56.
80. Tate EW. Recent advances in chemical proteomics: exploring the post-translational proteome. J Chem Biol 2008; 1: 17-26.
81. Romsicki Y, Kennedy BP, Asante-Appiah E. Purification and characterization of T cell protein tyrosine phosphatase reveals significant functional homology to protein tyrosine phosphatase-1B. Arch Biochem Biophys 2003; 414: 40-50.
82. Wälchli S, Curchod ML, Gobert RP, Arkinstall S, Hooft van Huijsduijnen R. Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A brute force approach based on substrate-trapping mutants. J Biol Chem 2000; 275: 9792-6.
83. You-Ten KE, Muise ES, Itié A, et al. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice. J Exp Med 1997; 186: 683-93.
84. Puius YA, Zhao Y, Sullivan M, Lawrence DS, Almo SC, Zhang ZY. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design. Proc Natl Acad Sci USA 1997; 94: 13420-5.
85. Salmeen A, Andersen JN, Myers MP, Tonks NK, Barford D. Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. Mol Cell 2000; 6: 1401-12.
86. Jia Z, Barford D, Flint AJ, Tonks NK. Structural basis for phosphotyrosine peptide recognition by protein tyrosine phosphatase 1B. Science 1995; 268: 1754-8.
87. Taing M, Keng YF, Shen K, Wu L, Lawrence DS, Zhang ZY. Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B. Biochemistry 1999; 38: 3793-803.
88. Xie L, Lee SY, Andersen JN, et al. Cellular effects of small molecule PTP1B inhibitors on insulin signaling. Biochemistry 2003; 42: 12792-804.
89. Guo XL, Shen K, Wang F, Lawrence DS, Zhang ZY. Probing the molecular basis for potent and selective protein-tyrosine phosphatase 1B inhibition. J Biol Chem 2002; 277: 41014-22.
90. Sun JP, Fedorov AA, Lee SY, et al. Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor. J Biol Chem 2003; 278: 12406-14.
91. Asante-Appiah E, Patel S, Dufresne C, et al. The structure of PTP-1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates. Biochemistry 2002; 41: 9043-51.
92. Lee SY, Liang F, Guo XL, et al. Design, construction, and intracellular activation of an intramolecularly self-silenced signal transduction inhibitor. Angew Chem Int Ed Engl 2005; 44: 4242-4.
93. Liang F, Lee SY, Liang J, Lawrence DS, Zhang ZY. The role of protein-tyrosine phosphatase 1B in integrin signaling. J Biol Chem 2005; 280: 24857-63.
94. Lee H, Xie L, Luo Y, et al. Identification of phosphocaveolin-1 as a novel protein tyrosine phosphatase 1B substrate. Biochemistry 2006; 45: 234-40.
95. Morrison CD, White CL, Wang Z, et al. Increased hypothalamic protein tyrosine phosphatase 1B contributes to leptin resistance with age. Endocrinology 2007; 148: 433-40.
96. Boutselis IG, Yu X, Zhang ZY, Borch RF. Synthesis and cell-based activity of a potent and selective protein tyrosine phosphatase 1B inhibitor prodrug. J Med Chem 2007; 50: 856-64.
97. Zhang S, Chen L, Luo Y, Gunawan A, Lawrence DS, Zhang ZY. Acquisition of a potent and selective TC-PTP inhibitor via a stepwise fluorophore-tagged combinatorial synthesis and screening strategy. J Am Chem Soc 2009; 131: 13072-9.
98. van Vliet C, Bukczynska PE, Puryer MA et al. Selective regulation of tumor necrosis factor-induced Erk signaling by Src family kinases and the T cell protein tyrosine phosphatase. Nat Immunol 2005; 6: 253-60.
99. Desmarais S, Friesen RW, Zamboni R, Ramachandran C. [Difluro(phosphono)methyl]phenylalanine-containing peptide inhibitors of protein tyrosine phosphatases. Biochem J 1999; 337 (Pt 2): 219-23.
100. Asante-Appiah E, Ball K, Bateman K, et al. The YRD motif is a major determinant of substrate and inhibitor specificity in T-cell protein-tyrosine phosphatase. J Biol Chem 2001; 276: 26036-43.
101. Skorey K, Waddleton D, Therien M, Leriche T. Enzyme occupancy measurement of intracellular protein tyrosine phosphatase 1B using photoaffinity probes. Anal Biochem 2006; 349: 49-61.
102. Dufresne C, Roy P, Wang Z, et al. The development of potent nonpeptidic PTP-1B inhibitors. Bioorg Med Chem Lett 2004; 14: 1039-42.
103. Thérien M, Skorey K, Zamboni R, et al. Synthesis of a novel peptidic photoaffinity probe for the PTP-1B enzyme. Bioorg Med Chem Lett 2004; 14: 2319-22.
104. Dufresne C, Roy P, Wang Z, et al. The development of potent nonpeptidic PTP-1B inhibitors. Bioorg Med Chem Lett 2004; 14: 1039-42.
105. Lau CK, Bayly CI, Gauthier JY, et al. Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors. Bioorg Med Chem Lett 2004; 14: 1043-8.
106. Scapin G, Patel SB, Becker JW, et al. The structural basis for the selectivity of benzotriazole inhibitors of PTP1B. Biochemistry 2003; 42: 11451-9.
107. Asante-Appiah E, Patel S, Desponts C, et al. Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase. J Biol Chem 2006; 281: 8010-5.
108. Li X, Bhandari A, Holmes CP, Szardenings AK. Alpha,alphadifluoro-beta-ketophosphonates as potent inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett 2004; 14: 4301-6.
109. Holmes CP, Li X, Pan Y, et al. Discovery and structure-activity relationships of novel sulfonamides as potent PTP1B inhibitors. Bioorg Med Chem Lett 2005; 15: 4336-41.
110. Holmes CP, Li X, Pan Y, et al. PTP1B inhibitors: synthesis and evaluation of difluoro-methylenephosphonate bioisosteres on a sulfonamide scaffold. Bioorg Med Chem Lett 2008; 18: 2719-24.
111. Moran EJ, Sarshar S, Cargill JF, Shahbaz MM, Lio A. Radiofrequency tag encoded combinatorial library method for the discovery of tripeptide-substituted cinnamic acid inhibitors of the protein tyrosine phosphatase PTP1B. J Am Chem Soc 1995; 117: 10787-8.
112. Fu H, Park J, Pei D. Peptidyl aldehydes as reversible covalent inhibitors of protein tyrosine phosphatases. Biochemistry 2002; 41: 10700-9.
113. Park J, Fu H, Pei D. Peptidyl aldehydes as slow-binding inhibitors of dual-specificity phosphatases. Bioorg Med Chem Lett 2004; 14: 685-7.
114. Park J, Fu H, Pei D. Peptidyl aldehydes as reversible covalent inhibitors of SRC homology 2 domains. Biochemistry 2003; 42: 5159-67.
115. Bleasdale JE, Ogg D, Palazuk BJ, et al. Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action. Biochemistry 2001; 40: 5642-54.
116. Larsen SD, Barf T, Liljebris C, et al. Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B. J Med Chem 2002; 45: 598-622.
117. Larsen SD, Stevens FC, Lindberg TJ, et al. Modification of the Nterminus of peptidomimetic protein tyrosine phosphatase 1B (PTP1B) inhibitors: identification of analogues with cellular activity. Bioorg Med Chem Lett 2003; 13: 971-5.
118. Liljebris C, Larsen SD, Ogg D, Palazuk BJ, Bleasdale JE. Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity. J Med Chem 2002; 45: 1785-98.
119. Szczepankiewicz BG, Liu G, Hajduk PJ, et al. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J Am Chem Soc 2003; 125: 4087-96.
120. Liu G, Szczepankiewicz BG, Pei Z, et al. Discovery and structureactivity relationship of oxalylarylaminobenzoic acids as inhibitors of protein tyrosine phosphatase 1B. J Med Chem 2003; 46: 2093-103.
121. Liu G, Xin Z, Liang H, et al. Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands. J Med Chem 2003; 46: 3437-40.
122. Xin Z, Oost TK, Abad-Zapatero C, et al. Potent, selective inhibitors of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett 2003; 13: 1887-90.
123. Pei Z, Li X, Liu G, et al. Discovery and SAR of novel, potent and selective protein tyrosine phosphatase 1B inhibitors. Bioorg Med Chem Lett 2003; 13: 3129-32.
124. Xin Z, Liu G, Abad-Zapatero C, et al. Identification of a monoacidbased, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B. Bioorg Med Chem Lett 2003; 13: 3947-50.
125. Combs AP, Yue EW, Bower M, et al. Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics. J Med Chem 2005; 48: 6544-8.
126. Yue EW, Wayland B, Douty B, et al. Isothiazolidinone heterocycles as inhibitors of protein tyrosine phosphatases: synthesis and structure-activity relationships of a peptide scaffold. Bioorg Med Chem 2006; 14: 5833-49.
127. Ala PJ, Gonneville L, Hillman MC, et al. Structural basis for inhibition of protein-tyrosine phosphatase 1B by isothiazolidinone heterocyclic phosphonate mimetics. J Biol Chem 2006; 281: 32784-95.
128. Combs AP, Zhu W, Crawley ML, et al. Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic. J Med Chem 2006; 49: 3774-89.
129. Ala PJ, Gonneville L, Hillman M, et al. Structural insights into the design of nonpeptidic isothiazolidinone-containing inhibitors of protein-tyrosine phosphatase 1B. J Biol Chem 2006; 281: 38013-21.
130. Sparks RB, Polam P, Zhu W, et al. Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett 2007; 17: 736-40.
131. Douty B, Wayland B, Ala PJ, et al. Isothiazolidinone inhibitors of PTP1B containing imidazoles and imidazolines. Bioorg Med Chem Lett 2008; 18: 66-71.
132. Klopfenstein SR, Evdokimov AG, Colson AO, et al. 1,2,3,4- Tetrahydroisoquinolinyl sulfamic acids as phosphatase PTP1B inhibitors. Bioorg Med Chem Lett 2006; 16: 1574-8.
133. Amarasinghe KK, Evdokimov AG, Xu K, et al. Design and synthesis of potent, non-peptidic inhibitors of HPTPbeta. Bioorg Med Chem Lett 2006; 16: 4252-6.
134. Hoffman BT, Nelson MR, Burdick K, Baxter SM. Protein tyrosine phosphatases: strategies for distinguishing proteins in a family containing multiple drug targets and anti-targets. Curr Pharm Des 2004; 10(10): 1161-81.
135. Pei Z, Liu G, Lubben TH, Szczepankiewicz BG. Inhibition of protein tyrosine phosphatase 1B as a potential treatment of diabetes and obesity. Curr Pharm Des 2004; 10(28): 3481-504.
136. Scott LM, Lawrence HR, Sebti SM, Lawrence NJ, Wu J. Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr Pharm Des 2010; 16(16): 1843-62.